PT  - JOURNAL ARTICLE
AU  - Daly, Rónán
AU  - Blackburn, Gavin
AU  - Mudaliar, Manikhandan
AU  - Burgess, Karl
AU  - Stirling, Anne
AU  - Porter, Duncan
AU  - McInnes, Iain
AU  - Barrett, Michael P.
AU  - Dale, James
TI  - Plasma Itaconate elevation following successful cDMARD treatment in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation
AID  - 10.1101/19001594
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 19001594
4099  - http://medrxiv.org/content/early/2019/07/08/19001594.short
4100  - http://medrxiv.org/content/early/2019/07/08/19001594.full
AB  - Objective To characterize changes in the plasma metabolic profile in newly diagnosed rheumatoid arthritis (RA) patients upon commencement of conventional disease modifying anti-rheumatic drug (cDMARD) therapy.Methods Plasma samples collected in an early RA randomized strategy study (NCT00920478) that compared clinical (DAS) disease activity assessment with musculoskeletal ultrasound assessment (MSUS) to drive treatment decisions were subjected to untargeted metabolomic analysis. Metabolic profiles were collected at pre- and 3 months post commencement of non-biologic cDMARD. Metabolites that changed in association with changes in the DAS44 score were identified at the 3 month timepoint.Results A total of ten metabolites exhibited a clear correlation with reduction in DAS44 score following cDMARD commencement, particularly itaconate, its derived anhydride and a derivative of itaconate coA. Increasing itaconate correlated with improved DAS44 score and decreasing levels of CRP.Conclusion cDMARD treatment effects invoke consistent changes in plasma detectable metabolites, that in turn implicate clinical disease activity with macrophages. Such changes inform RA pathogenesis and reveal for the first time a link between itaconate production and resolution of an inflammatory disease in humans. Quantitative metabolic biomarker based tests of clinical change in state are feasible and should be developed around the itaconate pathway.What is already known about this subject?Rheumatoid arthritis is associated with perturbations in metabolic activity, which have also been associated with response to certain treatments. In vitro work on immunometabolism has recently revealed itaconate as a key metabolite controlling macrophage activation.What does this study add?In newly diagnosed RA, commencement of csDMARD therapy is associated with changes in the levels of ten metabolites (especially itaconate and its derivatives) that correlate to a corresponding fall in disease activity Pathway analyses suggest these metabolites are associated with macrophage activation.How might this impact on clinical practice?Changes in metabolite levels in response to treatment provide additional new insights into RA pathogenesis that suggest a focus on macrophage activation state. The association of increased itaconate with decreased inflammation point to possible routes of intervention in RA.Competing Interest StatementRD, GB, KB, DP and MB have nothing to disclose. MM reports other support from CEREVANCE, LTD, outside the submitted work. AS reports grants from Pfizer UK, during the conduct of this survey. IM reports grants from Pfizer, grants from Chief Scientist Office, grants from ARUK, during the conduct of the study; grants and personal fees from BMS, personal fees from Abbvie, grants and personal fees from UCB, grants and personal fees from Pfizer, grants and personal fees from Janssen, personal fees from Lilly, outside the submitted work. JD reports grants from Chief Scientist’s Office, Scottish Government and from Pfizer UK during the conduct of the study; non-financial support from Abbvie UK, outside the submitted work.Clinical TrialNCT00920478Funding StatementThe TaSER study was jointly funded by a Clinical Academic Fellowship from the Chief Scientist?s Office, Scottish Executive and an Investigator Initiated project grant from Pfizer UK. The metabolomics study was funded by an additional Investigator Initiated project grant from Pfizer UK. RD was funded by Wellcome (105614/Z/14/Z). MPB is part of the Wellcome Centre for Molecular Parasitology funded by a core grant from Wellcome (104111/Z/14/Z).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesPlease contact the corresponding author in regards to accessing the experimental data.